Role of Precision Medicine in Oncology Clinical Trials: A New Era of Tailored Therapy

Abstract

Precision medicine is revolutionizing the field of oncology by enabling tailored therapies based on the genetic and molecular profile of individual tumors. This review explores the evolution of precision oncology, the design and implementation of precision-driven clinical trials, major technological advancements such as Next-Generation sequencing (NGS), and the incorporation of biomarkers and companion diagnostics. It also evaluates landmark precision oncology trials, such as NCI-MATCH, TAPUR, and SHIVA, and discusses the challenges and opportunities in regulatory, ethical, and economic aspects. Precision oncology offers hope for more effective and less toxic treatments, but its broader adoption requires addressing data interpretation, clinical validation, and access disparities. Furthermore, the integration of high-throughput sequencing technologies, molecular diagnostics, and bioinformatics tools has accelerated the identification of actionable mutations and patient-specific biomarkers. These advancements have led to the emergence of innovative trial designs such as basket, umbrella, and platform trials that increase the efficiency of drug development by matching therapies to molecular targets regardless of tumor origin.
Despite these promising developments, challenges such as regulatory complexities, data interpretation, and equitable access to genomic testing remain significant barriers. Ongoing research continues to refine patient stratification, therapeutic responsiveness, and trial methodologies, paving the way for a more personalized and effective oncology landscape.